The biotech company’s oncology treatments are so complex that generic drugmakers will have a hard time siphoning off revenue
Albert Bourla, CEO of Pfizer, highlighted the significance of the company's $43 billion acquisition of Seagen, a biotech firm specializing in cancer therapies. Through this acquisition, Pfizer aims to accelerate cancer research and bring new solutions to patients by combining Seagen's ADC technology with its own capabilities and expertise.
Our specially curated package of the most interesting articles to help you stay at the top of your game.
The innovative cancer drug maker is an appealing target for a pharma giant with plenty of cash to spend
Pfizer said the study, which has been peer-reviewed and published in the Lancet Neurology journal, showed the company's drug zavegepant had proven to be "effective in the acute treatment" of migraines and had few apparent side effects.
Nevatia succeeds S Sridhar who announced his early retirement in August 2022. Sridhar will be stepping down as managing director with close of business hours on March 31, 2023.
Tagging a video of Pfizer CEO Albert Bourla's encounter with a journalist in Davos, Chandrasekhar said on Twitter that the pharmaceutical company tried to bully the Indian government into accepting conditions of indemnity.
Pfizer had sought an emergency use authorisation for its jab in December 2020 but withdrew the proposal in February 2021 after failing to meet the drug regulator’s demand for a local safety study
The drug will be retailed in the Indian market at an 85 percent reduction from the current MRP to increase affordability and access, the pharma company has said
US-based Pfizer has signed a licensing agreement for Paxlovid with 30 drugmakers globally, including 19 Indian companies. Hetero and Zenara have said they received regulatory approvals for their versions of Paxlovid
Paternity leaves are increasingly becoming the norm at many workplaces, breaking the stereotype of childcare primarily being the mother's responsibility.
The selling can be extended in the coming sessions with support at 18,100-18,000 levels, however, on the higher side, the index may face hurdles at 18,500-18,700 levels if it holds these supports
The momentum is intact and the Friday's correction is on expected lines given the consistent uptrend in the past. Hence, once the current consolidation ends, the Nifty50 is expected to resume upward journey once again towards 18,900-19,000 levels in coming days, with crucial supports at 18,500-18,300, experts said
According to sales data for the 12‐month period ending September 2022, the Inlyta Tablets, 1 mg and 5 mg, achieved annual sales of approximately $644.5 million
ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4505 in its research report dated November 17, 2022.
Breaching either side of 18,200-18,450 range can give some kind of direction to the market in the coming days, but having a monthly expiry and FOMC minutes scheduled this week, volatility and consolidation is at the top before any kind of big move on either side of range
Antibody levels against the variant rose nearly 9 times in older adults, aged 55 and above, who received the Omicron shot compared to a 2-fold increase in participants with the original shot, according to data posted on the online archive bioRxiv.
The S&P 500 fell 0.5% as of 12:50 p.m. Eastern. It had been up as much as 1% shortly after trading opened. The Dow Jones Industrial Average fell 129 points, or 0.4%, to 32,604 and the Nasdaq fell 0.8%.
The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this year.
MCX India has witnessed a breakout of a bullish double bottom pattern formation on the longer time frame while on the daily chart; it has given a breakout of a bullish Inverse Head & Shoulder pattern with huge volume.
More than 375 million doses of the original vaccine, which Pfizer developed with the German drugmaker BioNTech, have been distributed in the U.S., according to the Centers for Disease Control and Prevention.
Healthcare Global Enterprises has broken out from the horizontal channel on the weekly charts. Price breakout is accompanied by jump in volumes. It is placed above all important moving averages, which indicates bullish trend on all time frames.